Journal of the Endocrine Society · 2026
Medical therapy in mild autonomous cortisol secretion.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kelsall Alan, Agboola Michelle, Bryden Evie, Healey William, Tolhurst Katherine, Hind Daniel, Newell-Price John
Аннотация
BACKGROUND: Mild autonomous cortisol secretion (MACS) has an increasing prevalence with age and is associated with cardiometabolic comorbidity and increased mortality. Current guidelines recommend the majority of patients with MACS be managed conservatively, with select people referred for laparoscopic adrenalectomy. There are currently no licensed medications for MACS.
OBJECTIVE: We aimed to systematically review the literature to map out the current available evidence on the use of medical therapy in the treatment of MACS and to assess the research gap. Additionally, we sought to establish the outcome measurements used, to inform the design of future prospective clinical trials.
DESIGN: We searched MEDLINE and EMBASE from conception as well as clinical trial registries to detect all original studies of medical treatments in MACS. Titles and abstracts were screened and full articles reviewed.
RESULTS: A total of 5369 results were found from the search strategy. Thirteen studies met the inclusion criteria, of which 8 were conference abstracts and 5 full-text studies were included in the final analysis. This included 2 studies of metyrapone and 3 studies that used mifepristone. Common outcome measures included blood pressure, glucose measurements, weight, and side effect data.
CONCLUSION: There is a considerable knowledge gap with regard to the medical management of MACS. Current available evidence consists of a handful of small, heterogeneous studies with a suggestion of a potential benefit in initiating mifepristone or metyrapone in this cohort. Our results highlight the urgent need for larger, prospective studies. To support this, we have provided suggestions for outcome measures.
OBJECTIVE: We aimed to systematically review the literature to map out the current available evidence on the use of medical therapy in the treatment of MACS and to assess the research gap. Additionally, we sought to establish the outcome measurements used, to inform the design of future prospective clinical trials.
DESIGN: We searched MEDLINE and EMBASE from conception as well as clinical trial registries to detect all original studies of medical treatments in MACS. Titles and abstracts were screened and full articles reviewed.
RESULTS: A total of 5369 results were found from the search strategy. Thirteen studies met the inclusion criteria, of which 8 were conference abstracts and 5 full-text studies were included in the final analysis. This included 2 studies of metyrapone and 3 studies that used mifepristone. Common outcome measures included blood pressure, glucose measurements, weight, and side effect data.
CONCLUSION: There is a considerable knowledge gap with regard to the medical management of MACS. Current available evidence consists of a handful of small, heterogeneous studies with a suggestion of a potential benefit in initiating mifepristone or metyrapone in this cohort. Our results highlight the urgent need for larger, prospective studies. To support this, we have provided suggestions for outcome measures.